# Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)

> **NCT06972758** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 60 (estimated)

## Conditions studied

- Carcinom
- Hepatocellular

## Interventions

- **DRUG:** Certirobell®

## Key facts

- **NCT ID:** NCT06972758
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2030-07-01
- **Final completion:** 2030-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972758, "Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06972758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*